Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Fsd Pharma Inc Cl B (CSE:HUGE)

0.1250 UNCHANGED
Last Price Updated: 3:58 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fsd Pharma Inc Cl B

< Previous 1 2 3 4 5 6 7 8 Next >
FSD Pharma Inc. Announces Closing of Private Placement
Via ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), Celly Nu Complete Plan of Arrangement
Via Investor Brand Network
FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement
Via ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Issues update on GBB Drink Lab Inc. Litigation and Safety Shot
Via Investor Brand Network
Topics Lawsuit
Exposures Financial Legal
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness
Via ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in Goldman Small Cap Research Report, Receives Approval for Celly Nu Plan of Arrangement
Via Investor Brand Network
Exposures Product Safety
FSD Pharma Inc. Obtains Final Order for Plan of Arrangement
Via ACCESSWIRE
Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.
Via ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Approval of the Plan of Arrangement with Celly Nu
Via Investor Brand Network
FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.
Via ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Date for Planned Distribution of Celly Nu Shares
Via Investor Brand Network
FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement
Via ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Filing of Supplement to Management Information Circular
Via Investor Brand Network
FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023
Via ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Status Update on Proposed Celly Nu Dividend Distribution
Via Investor Brand Network
FSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One Basis
Via ACCESSWIRE
FSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus
Via ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Filing in Connection with Proposed Arrangement with Celly Nu
Via Investor Brand Network
FSD Pharma Files Management Information Circular for Proposed Arrangement with Celly Nu
Via ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media
Via Investor Brand Network
FSD Pharma and Celly Nu Enter Into Arrangement Agreement
Via ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Dismissal of Motion, Wins $2.8 Million Award
Via Investor Brand Network
FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice
Via ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video
Via Investor Brand Network
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Interim Results from FIH Clinical Trial of Lucid-MS
Via Investor Brand Network
FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated
Via ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Coverage Initiated by Singular Research
Via Investor Brand Network
FSD Pharma Announces Analyst Coverage Initiated by Singular Research
Via ACCESSWIRE
FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present Phase 1 Data on Lucid-MS at Milan Peer Conference
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.